| [1] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. doi: 10.3322/caac.21834.
|
| [2] |
冯征, 郭勤浩, 朱俊. 2023年度妇科恶性肿瘤治疗进展及展望[J]. 中国癌症杂志, 2024, 34(4):340-360. doi: 10.19401/j.cnki.1007-3639.2024.04.002.
|
| [3] |
Bartolomucci A, Nobrega M, Ferrier T, et al. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology[J]. NPJ Precis Oncol, 2025, 9(1):84. doi: 10.1038/s41698-025-00876-y.
pmid: 40122951
|
| [4] |
Fathi A, Heidari M, Rasouli J, et al. Diagnostic value of the Risk of Ovarian Malignancy Algorithm (ROMA) index in the detection of ovarian cancer in postmenopausal women: a systematic review and meta-analysis[J]. BMC Womens Health, 2025, 25(1):280. doi: 10.1186/s12905-025-03766-4.
pmid: 40474158
|
| [5] |
Zou Z, Xia L, Tang S, et al. Diagnostic Value of PET/CT for Ovarian Cancer Recurrence or Metastasis in Postoperative Patients With Elevated Serum CA125 Levels: A Systematic Review and Meta-Analysis[J]. Cancer Innov, 2025, 4(4):e70015. doi: 10.1002/cai2.70015.
|
| [6] |
Zhou J, Mo H, Hu D, et al. Association of ctDNA detection and recurrence assessment in patients with neoadjuvant treatment[J]. Cancer Med, 2023, 12(19):19794-19806. doi: 10.1002/cam4.6544.
|
| [7] |
Wan J, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA[J]. Nat Rev Cancer, 2017, 17(4):223-238. doi: 10.1038/nrc.2017.7.
pmid: 28233803
|
| [8] |
Xia T, Fang C, Chen Y. Advances in application of circulating tumor DNA in ovarian cancer[J]. Funct Integr Genomics, 2023, 23(3):250. doi: 10.1007/s10142-023-01181-2.
|
| [9] |
Zelli V, Compagnoni C, Cannita K, et al. Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer[J]. High Throughput, 2020, 9(1):1. doi: 10.3390/ht9010001.
|
| [10] |
Cohen SA, Liu MC, Aleshin A. Practical recommendations for using ctDNA in clinical decision making[J]. Nature, 2023, 619(7969):259-268. doi: 10.1038/s41586-023-06225-y.
|
| [11] |
Roussel-Simonin C, Blanc-Durand F, Tang R, et al. Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid[J]. Mol Cancer, 2023, 22(1):178. doi: 10.1186/s12943-023-01864-1.
pmid: 37932736
|
| [12] |
Fu Y, Xu Y, Liu W, et al. Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma[J]. EClinicalMedicine, 2024, 73:102697. doi: 10.1016/j.eclinm.2024.102697.
|
| [13] |
Fu R, Huang J, Tian X, et al. Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study[J]. Mol Oncol, 2023, 17(5):825-838. doi: 10.1002/1878-0261.13387.
pmid: 36732646
|
| [14] |
Raab M, Kostova I, Peña-Llopis S, et al. Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer[J]. Cancer Commun(Lond), 2024, 44(1):101-126. doi: 10.1002/cac2.12511.
|
| [15] |
Pascual J, Attard G, Bidard FC, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group[J]. Ann Oncol, 2022, 33(8):750-768. doi: 10.1016/j.annonc.2022.05.520.
pmid: 35809752
|
| [16] |
Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial[J]. Lancet Oncol, 2016, 17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X.
pmid: 27617661
|
| [17] |
Kim YN, Shim Y, Seo J, et al. Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA-Mutated Ovarian Cancer[J]. Clin Cancer Res, 2023, 29(14):2725-2734. doi: 10.1158/1078-0432.CCR-22-3715.
|
| [18] |
Buckley DN, Lewinger JP, Gooden G, et al. OvaPrint-A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer[J]. Clin Cancer Res, 2023, 29(24):5196-5206. doi: 10.1158/1078-0432.CCR-23-1197.
pmid: 37812492
|
| [19] |
Terp SK, Stoico MP, Dybkær K, et al. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review[J]. Clin Epigenetics, 2023, 15(1):24. doi: 10.1186/s13148-023-01440-w.
pmid: 36788585
|
| [20] |
S SK, Swamy SN, Premalatha CS, et al. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma[J]. Asian Pac J Cancer Prev, 2019, 20(10):3001-3005. doi: 10.31557/APJCP.2019.20.10.3001.
|
| [21] |
Liang L, Zhang Y, Li C, et al. Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer[J]. EBioMedicine, 2022, 83:104222. doi: 10.1016/j.ebiom.2022.104222.
|
| [22] |
Jamshidi A, Liu MC, Klein EA, et al. Evaluation of cell-free DNA approaches for multi-cancer early detection[J]. Cancer Cell, 2022, 40(12):1537-1549.e12. doi: 10.1016/j.ccell.2022.10.022.
pmid: 36400018
|
| [23] |
Vavoulis DV, Cutts A, Thota N, et al. Multimodal cell-free DNA whole-genome TAPS is sensitive and reveals specific cancer signals[J]. Nat Commun, 2025, 16(1):430. doi: 10.1038/s41467-024-55428-y.
|
| [24] |
Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer[J]. Nature, 2019, 570(7761):385-389. doi: 10.1038/s41586-019-1272-6.
|
| [25] |
Wang F, Wang L, Xing Z, et al. Multi-analyte approach combining cfDNA sequencing and protein testing for early ovarian cancer detection[J]. iScience, 2025, 28(6):112617. doi: 10.1016/j.isci.2025.112617.
|
| [26] |
An Y, Zhao X, Zhang Z, et al. DNA methylation analysis explores the molecular basis of plasma cell-free DNA fragmentation[J]. Nat Commun, 2023, 14(1):287. doi: 10.1038/s41467-023-35959-6.
pmid: 36653380
|